Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01654068 |
Recruitment Status :
Terminated
(low participant accrual)
First Posted : July 31, 2012
Results First Posted : April 19, 2019
Last Update Posted : April 19, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Vertebral Metastasis | Radiation: Conformal High Dose Intensity Modulated Radiation Therapy | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 14 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Conformal High Dose Intensity Modulated Radiation Therapy for Asymptomatic Metastatic Disease to the Thoracic and Lumbar Spine |
Actual Study Start Date : | December 9, 2009 |
Actual Primary Completion Date : | April 22, 2016 |
Actual Study Completion Date : | September 8, 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: Radiation Therapy to Local Spine Metastasis
Conformal High Dose Intensity Modulated Radiation Therapy to a single asymptomatic local spine metastasis.
|
Radiation: Conformal High Dose Intensity Modulated Radiation Therapy
Conformal High Dose Intensity Modulated Radiation Therapy 14-16Gy single fraction dosing using 6MV photons |
- Time to Any Skeletal Related Event [ Time Frame: up to 24 months ]Time to any skeletal related event most commonly symptomatic recurrence or progression with pain/neurologic impairment with evidence of radiographic progression (median local progression-free survival).
- Acute Radiation Toxicity [ Time Frame: 90 days ]The number of acute side effects of radiation therapy will be documented (≤ 90 days from start of radiation therapy)
- Late Radiation Toxicity [ Time Frame: 2 years ]The number of late side effects of radiation therapy will be documented (> 90 days after the start of radiation therapy)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histological confirmation of malignancy (non-small cell lung cancer, breast cancer (hormone refractory), prostate cancer (hormone refractory), lymphoma, renal cell carcinoma, myeloma by either biopsy or cytology of the primary or metastatic lesion.
- Patients must have radiological documentation of metastatic disease to the thoracic or lumbar spine including both positron emitted tomography (PET) or nuclear medicine bone scan (NMBS) and Magnetic Resonance Imaging (MRI) within 4 weeks prior to study entry.
- Patients with one to three spinal metastases to the thoracic or lumbar spine will be included.
- Spinal metastatic lesions should be limited to one vertebral body level or ≤ 6cm in greatest dimension.
- Tumors should not directly abut the spinal cord, and have at least 5mm separation from the spinal cord. For patients with tumors closer than 5mm, inclusion is permissible at the discretion of the treating radiation oncologist such that dosimetric review demonstrates that the total dose to spinal cord is within tolerable range of <10Gy to 10% partial volume or max point dose 18 Gy.
- Patients must be able to fit into either the Elekta Stereotactic Body Frame or the Elekta Stereotactic BodyFix immobilization device.
- Must be ≥ 18 years of age.
- ECOG status 0-2.
- Women of childbearing potential and male participants must use an effective contraception method. (Until at least 60 days following treatment.)
- Negative urine pregnancy test within at least one week before starting treatment in women of child-bearing age.
- Patients must sign a study-specific informed consent form.
Exclusion Criteria:
- Patients with evidence of spinal instability OR neurologic deficit resulting from bony compression of neurologic structures.
- Patients with other systemic illness, or have not recovered adequately from their primary treatment or who have evidence of progression of their current cancer prior to therapy that, in the investigator's opinion, would preclude their inclusion.
- Patient may not receive concomitant cytotoxic anti-neoplastic therapy during treatment. Patients may be allowed to use hormonal suppression therapy or bisphosphonates for hypercalcemia.
- Pregnant or lactating women.
- Any patient with symptoms of pain, compression fracture, neurologic deficit will not be included.
- Patients previously treated with radiation therapy to the thoracic or lumbar spinal levels of involved disease will not be included.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01654068
United States, Kentucky | |
University of Kentucky | |
Lexington, Kentucky, United States, 40536 |
Principal Investigator: | Ronald McGarry, M.D. | University of Kentucky |
Documents provided by Ronald McGarry, University of Kentucky:
Responsible Party: | Ronald McGarry, Professor, Radiation Medicine, University of Kentucky |
ClinicalTrials.gov Identifier: | NCT01654068 |
Other Study ID Numbers: |
MCC-09-RAD-01 |
First Posted: | July 31, 2012 Key Record Dates |
Results First Posted: | April 19, 2019 |
Last Update Posted: | April 19, 2019 |
Last Verified: | March 2019 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
Female Breast Cancer Kidney Cancer Lung Cancer Prostate Cancer Vertebral metastasis |
Neoplasm Metastasis Neoplastic Processes Neoplasms Pathologic Processes |